DividendInvestor.com

Nine dividend-paying oil investments to purchase as the economy heats up and energy prices climb belong to an industry that will be fueled by $100 a barrel Brent crude in 2022, according to a recent report by BoA Global Research.

The nine dividend-paying oil investments to purchase amid the improving economy and rising oil prices include four funds, the country’s biggest refiner of the so-called “black gold” and five stocks that BoA rates as “buy.” The forecast of $100 a barrel for Brent crude next year came from BoA’s commodity team, even though its equity research colleagues are not quite as bullish.

Pension Chairman Predicts Oil Rising to $100 a Barrel and Recommends Two of the Nine Dividend-paying Oil Investments to Purchase

Aside from short-term dips, oil has been a good investment for more than a year, and its ascent is likely to continue, said Bob Carlson, who heads the Retirement Watch investment newsletter. Market forces and the major oil producers are expected to drive the price of oil to around $100 and it likely will remain near that level, if global economic growth stays strong, he added.

“I prefer to invest in the commodities themselves instead of companies in commodity businesses,” said Carlson, who further serves as chairman of the Board of Trustees of Virginia’s Fairfax County Employees’ Retirement System with more than $4 billion in assets. “Investing in the commodities avoids potential problems with management, debt levels, regulators, labor and more.”

Funds are the “best way” for most investors to take stakes in commodities, Carlson counseled.

Pension fund and Retirement Watch chief Bob Carlson answers questions from columnist Paul Dykewicz.

A Commodity Fund Is Another of the Nine Dividend-paying Oil Investments to Purchase

A good choice for investors is the ETF iShares GSCI Commodity Dynamic Roll (COMT), Carlson continued. The fund seeks to follow the Goldman Sachs Commodity Index, which is heavily weighted to energy compared to most other commodity indexes, he added.

Chart courtesy of www.StockCharts.com

COMT invests in most commodities using futures contracts. The fund has gained 9.30% in the last three months and 28.27% for the year to date.

“Another good choice is Parametric Commodity Strategy (EAPCX), an open-end mutual fund,” Carlson said. “This fund also takes most of its commodity positions through futures contracts. The fund’s benchmark is the Bloomberg Commodity Total Return Index, which isn’t as heavily weighted in energy as the GSCI.”

Chart courtesy of www.StockCharts.com

However, EAPCX does not try to track the Bloomberg Commodity Total Return Index, Carlson commented. Instead, EAPCX seeks to beat the index using a rules-based systematic investment process, greater diversification and active rebalancing, he added.

“The managers don’t forecast the markets or take positions based on forecasts,” Carlson told me.

The fund has risen 8.67% in the last three months and 22.87% for the year date.

Seasoned Wall Street Trader Chooses Largest U.S. Oil Refiner as One of Nine Dividend-paying Oil Investments to Purchase

“Oil prices topped out in mid-July after OPEC stated it would increase production,” said Bryan Perry, who heads the Cash Machine investment newsletter, as well as the Premium Income, Quick Income Trader, Breakout Profits Trader and Hi-Tech Trader advisory services. As of July 19, WTI crude traded at $66.57/bbl. in what is the sharpest sell-off since late March. Assuming this pullback in crude is an orderly correction, following a torrid move higher year to date, it presents a compelling buying opportunity in some blue-chip energy stocks.”

Paul Dykewicz interviews Bryan Perry.

One such stock that Perry recommends is Findlay, Ohio-based Marathon Petroleum Corp. (NYSE:MPC), America’s largest oil refiner. Perry called Marathon his favorite industry pick right now. Marathon not only has robust operations in refining but in midstream and retail markets, he added.

Chart courtesy of www.StockCharts.com

Recommended Refiner’s Resurgence Rates It One of Nine Dividend-paying Oil Investments to Purchase

Revenues at Marathon are forecast to rise by 23% to $85 billion in 2021 with earnings of $1.03 per share estimated to soar by 221% to $3.31 in 2022, Perry said. The stock traded at $64.84 in early June and is testing its 200-day moving average around $50, offering a dividend yield of 4.5%, Perry continued.

If oil prices stabilize, Marathon Petroleum should prove to be a “very savvy purchase” for investors who want to initiate or add to their energy holdings, Perry predicted.

Nine Dividend-paying Oil Investments to Purchase Gain Economic Support from Stock-Savvy Professor

The 13-nation Organization of Petroleum Exporting Countries (OPEC) and its oil-producing allies recently agreed to provide millions of additional barrels of crude oil a day to the global market in the next couple of years, said Mark Skousen, PhD, who leads the Forecasts & Strategies investment newsletter, as well as the Five Star Trader, Home Run Trader, TNT Trader and the Fast Money Alert trading services. So, it is not surprising that the price of U.S. oil has dropped by 6% to less than $70 on Monday, July 19, added Skousen, a Presidential Fellow in economics at Chapman University.

The drop in oil prices hurt energy producers, since the sector was enduring a shakeout due to recent consolidation in the stock market. But a good contrarian buys on bad news with a view to taking profits when the outlook improves, Skousen said.

With the pandemic receding, interest rates near record lows and governments introducing multi-trillion fiscal stimulus around the world, it should not be long before oil prices and companies rebound, Skousen opined.

Mark Skousen, PhD, a descendent of Benjamin Franklin, meets with Paul Dykewicz in Philadelphia.

Money Manager Favors a Fund Among the Nine Dividend-paying Oil Investments to Purchase

“I’m going to get contrarian here: while oil might spike above $100 on a supply shock or geopolitical tension, it’s going to take a lot of inflation and a lot of OPEC supply discipline to keep it there,” said Hilary Kramer, who heads the GameChangers and Value Authority advisory services. “This is not the 1970s, when U.S. energy independence was a cruel dream. If overseas producers talk tough, domestic shale operators will simply drill more wells. So, what do I like in the sector? All the majors are down 10-25%, so all you really need to do is pick up a broad market-cap-weighted basket like the Energy SPDR (NYSE:XLE) and wait for rising crude to lift all the boats.”

Chart courtesy of www.StockCharts.com

For investors who want to buy a more concentrated oil allocation, an outside-the-box idea is natural gas processor Williams Companies (NYSE:WMB), which offers an implied yield of 6.4% and is showing significant stress, Kramer counseled.

Chart courtesy of www.StockCharts.com

“I’d be surprised if cash flow on the horizon will support the dividend, so the market is right in being a little leery of this stock, Kramer said. “But while it will take some creative accounting to maintain a $0.41 quarterly payout, I’m thinking WMB can manage $0.30 per quarter without too much trouble… if management decides they need to cut at all. That’s worth a 4.5% yield, which is pretty good if you’re simply looking for a bond replacement over the next few years.”

Paul Dykewicz interviews money manager Hilary Kramer. Her premium advisory services include IPO Edge, 2-Day Trader, Turbo Trader and the exclusive Inner Circle.

And that possibility is a “worst-case scenario,” Kramer said. WMB’s management found a way to keep hiking its dividend in every oil slump since 2002, with the only cut occurring in 2016 to free up cash for acquisitions, she added.

“At the time, Wall Street cheered,” Kramer recalled. “While I can’t promise that this time around, using this stock for income and not as a trading vehicle is probably the way to go right now.”

BoA Global Research Identifies Five of Nine Dividend-paying Oil Investments to Purchase

A recent research report by BoA identified five oil stocks as buys. Exxon Mobil Corp. stands out at the top of the group.

Key risks faced by Exxon Mobil include a challenging margin environment, significant delays to the new upstream projects critical to its growth targets and obstacles to capturing the price climate due to cost constraints. However, BoA set a lofty $90 price target for Exxon Mobil, 57.8% above its closing price of $57.05 on July 23.

Chart courtesy of www.StockCharts.com

Occidental Petroleum Corp. (NYSE:OXY) received a $44 price target from BoA that would mark a 65.5% jump from the company’s closing price of $26.58 on July 23. But the company’s downside risks, cited by BoA, include the tough oil and gas environment, potential delays in large-scale projects and exposure to the Middle East and the corresponding political risk it entails.

Chart courtesy of www.StockCharts.com

Hess Earns Spot Among Six Oil Stocks to Buy

Hess Corp. (NYSE:HES) received a price objective of $115 from BoA, 54.6% above its closing stock price of $74.38 on July 23. BoA cautioned to expect the company to show restraint on new spending projects to grow its business. The risks to the forecast include the unpredictable pricing environment, potential slowdowns in drilling that could cause production to slide below expectations and exploratory drilling activities that may hold back the stock’s climb, BoA indicated.

Chart courtesy of www.StockCharts.com

FANG Earns Berth Among Nine Dividend-paying Oil Investments to Purchase

Diamondback Energy Inc. (NYSE:FANG) garnered a $114 price objective from BoA, 45.7% above the stock’s closing share price of $78.23 on July 23. However, its risks include the uncertain pricing environment in the oil industry and a possible slower rate of development than now expected.

Chart courtesy of www.StockCharts.com

Deven Energy Also Is One of the Nine Dividend-paying Oil Investments to Purchase

Deven Energy Corp. (NYSE:DYN) received a $40 price objective from BoA, 56.1% above the stock’s closing share price of $25.63 on July 20. Challenges include trying to develop production in the Permian Basin and Eagle Ford shale, weak natural gas pricing and a potential global recession, according to BoA.

Chart courtesy of www.StockCharts.com

New Delta Variant of COVID-19 Spread May Affect Nine Dividend-paying Oil Investments to Purchase

The increasingly transmissible Delta variant of COVID-19 has heightened concerns from health experts about the growing spread of the virus across the United States. The variant is blamed for new surges in case numbers and deaths. Genetic variants of SARS-CoV-2 have been emerging and circulating around the world since the start of the COVID-19 pandemic, according to the Centers for Disease Control and Prevention (CDC).

Recently, the CDC and the U.S. State Department each raised their warnings to the highest levels on July 19 for travel to the United Kingdom. The CDC warned to “avoid” traveling there, while the State Department issued a “do not travel” order to prevent visiting the United Kingdom.

The definition of a a variant is that is has one or more mutations that differentiate it from other COVID-19 varieties. The CDC expects the Delta variant to become the dominant coronavirus strain in the United States. With more than half the U.S. population not fully vaccinated, public health officials caution that a resurgence of COVID-19 cases is starting to occur and may worsen further this fall when many unvaccinated children return to school.

Progress in boosting the number of people vaccinated from COVID-19 raises hope that new cases and deaths will fall. As of July 23, 187,579,557 people, or 56.6% of the U.S. population, have received at least one dose of a COVID-19 vaccine. Those in American who are fully vaccinated total 162,435,276 people, or 48.9%, of the U.S. population, according to the CDC.

The Food and Drug Administration recently approved a third COVID-19 vaccine, manufactured by Johnson & Johnson (NYSE:JNJ), which requires just one dose rather than two doses, as with the first two vaccine providers: Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

COVID-19 cases worldwide have reached 192,939,490 and caused 4,140,700 deaths, as of July 23, according to Johns Hopkins University. U.S. COVID-19 cases reached 34,316,321 and caused 610,387 deaths. America has the dreaded distinction as the country with the most COVID-19 cases and deaths.

The nine dividend-paying oil investments to purchase offer investors a chance to profit and be paid for their patience amid the pandemic. Increasing COVID-19 vaccine availability and doses, improving economic data and a recent $1.9 trillion federal stimulus package should help to boost the prices of the nine dividend-paying oil investments to purchase.

Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street Journal, Investor’s Business Daily, USA Today, the Journal of Commerce, Seeking Alpha, GuruFocus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great as a gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many others. Call 202-677-4457 for special pricing!

Just 30 stocks make our list of every dividend stock trading under $5.

For the price of a cup of coffee, you can own a small piece of a company — one that pays you cash on a regular basis. This is a tempting thought, and one worth considering, but with caution.

Many of these companies offer growth potential and pay high dividends, while others are likely to maintain their value and some are risky traps for over-eager investors. Regardless, dividend stocks trading under $5 offer an opportunity to different kinds of investors.

Those who are new to dividend stocks — or investing in general — may prefer to dip their toe in and only purchase a few dollars worth of stocks. Other investors may want to dial an exact amount of money with their investment without requiring fractional shares.

The collection of these 30 dividend stocks trading under $5 is charted below, alongside the S&P 500 for comparison — these stocks generally follow the index, with an exception in the trailing month. This, however, may be the result of selection bias, as the list of dividend stocks trading under $5 changes on a daily basis. A share price drop could suddenly put a company under the $5 threshold, and quick success may jolt the company past it.

As a result, there are a few inclusions with poor performance in the recent past that are likely bringing the average growth percentage down.

Chart provided by StockRover, start your free trial here.

The speed at which these stocks change is worth noting as well. The list of dividend stocks trading under $5 was last updated to reflect the end of day prices on July 19, 2021. The price, dividend yield and other metrics shown in the table below, however, are automatically updated and correct. Hence, pending when this list is viewed, there may be some stocks included above the $5 threshold and some excluded who will be added to the list in the next update.

Listed below is every dividend stock trading under $5. They are ranked in ascending order by their dividend yield below.

Ticker	Sector	Consecutive Annual Dividend Hikes	Market Cap	Latest Close Price	Projected 12 Month Dividend Yield	Trailing 12 Month Dividend Yield
CPG	Energy	0	$1.71B	$3.38	Currency Mismatch	Currency Mismatch
ABEV	Consumer Products	1	$50.43B	$3.21	0.31%	2.53%
SVM	Materials	0	$795.86M	$4.77	0.63%	0.52%
SAN	Financials	0	$16.87B	$3.62	3.31%	3.44%
BBD	Financials	0	$21.70B	$4.58	0.87%	3.62%
DHC	Financials	0	$922.10M	$3.87	1.03%	1.03%
LYG	Financials	0	$3.45B	$2.42	2.48%	1.33%
SUPV	Financials	0	$0	$1.98	0.51%	0.68%
HMY	Materials	0	$686.14M	$4.06	1.29%	1.52%

AUY	Materials	2	$3.83B	$4.09	2.69%	2.35%
BEDU	Services	1	$0	$4.09	2.69%	N/A
AEG	Financials	0	$8.63B	$4.10	3.41%	3.51%
BRW	Financials	0	$624.60M	$4.56	3.51%	3.61%
BTG	Materials	1	$4.12B	$4.00	4.00%	4.00%
BBDO	Financials	0	$0	$4.00	0.75%	3.77%
MFG	Financials	3	$0	$2.80	5.00%	5.02%
NCMI	Services	0	$283.73M	$3.51	5.70%	6.84%
MFA	Financials	0	$2.02B	$4.57	8.75%	6.56%
NMR	Financials	2	$9.83B	$5.00	6.60%	6.56%
CIG__C	Utilities	1	$0	$2.76	2.90%	6.23%
TKC	IT & Communications	0	$3.99B	$4.53	1.77%	3.52%
ENIC	Utilities	1	$0	$2.83	11.31%	5.60%
FLMN	Energy	0	$226.89M	$4.91	8.15%	5.50%
NYMT	Financials	0	$1.65B	$4.36	8.72%	8.60%

BKCC	Financials	0	$287.71M	$3.88	10.31%	10.31%
NAT	Industrials	2	$404.36M	$2.67	10.49%	10.49%
IVR	Financials	0	$850.07M	$3.45	8.99%	8.99%
TEF	IT & Communications	0	$22.09B	$4.37	10.76%	10.84%

Dividend increases and dividend decreases, new dividend announcements, dividend suspensions and other dividend changes occur daily. To make sure you don’t miss any important announcements, sign up for our E-mail Alerts. Let us do the hard work of gathering the data and sending the relevant information directly to your inbox. In addition to E-mail Alerts, you will have access to our powerful dividend research tools. Take a quick video tour of the tools suite.

Jonathan Wolfgram is an editorial staffer who writes website content at Eagle Financial Publications. He graduated from the University of Minnesota with Bachelor’s degrees in Finance and Philosophy. Jonathan writes for www.DividendInvestor.com and www.StockInvestor.com.

Two dividend paying generic pharmaceutical stocks to buy for income highlight companies arguably near the top of that sector.

The two dividend-paying generic pharmaceutical stocks to buy are especially appealing because they can produce further growth organically and through acquisitions. One trade-off is that the two dividend-paying generic pharmaceutical stocks lack the blockbuster potential of companies that launch promising new drugs aimed at huge potential markets that could cause their share prices to soar.

One of the two dividend-paying generic pharmaceutical manufacturers to buy is from the generic drug hotbed of India, while the other is from the United States. Dr. Reddy’s Laboratories, based in India, may have one of the most recognized brands in the generic industry because it was founded and named after Kallam Anji Reddy, PhD, who earned his doctorate in Chemical Engineering from India’s National Chemical Laboratory.

Source: Stock Rover. Click here to sign up for a free two-week trial.

For investors looking to gain exposure to generic pharmaceutical companies, consider India, which has become a “global powerhouse” in the industry, said Bob Carlson, leader of the Retirement Watch investment newsletter.

Pension fund and Retirement Watch leader Bob Carlson answers questions from Paul Dykewicz.

Dr. Reddy’s Laboratories Heads Two Dividend-paying Generic Pharmaceutical Stocks to Buy

Among India’s top generic drug stocks for investors are Dr. Reddy’s Laboratories (NYSE:RDY), Sun Pharmaceutical industries (524715.India), Divi’s Laboratories (532488.India) and Cipla (500087.India). However, the generic sector of the pharmaceutical industry has had problems, Carlson cautioned.

The industry has been under fire for overpricing generic drugs, Carlson continued. U.S. pharmacies and other buyers have consolidated further than in the past and are negotiating reduced prices with the generic drug makers as the sector has faced several government investigations, he added.

In its fourth-quarter 6-K document filed with the U.S. Securities and Exchange Commission (SEC), Dr. Reddy’s Laboratories reported that it is involved in disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings, including patent and commercial matters that arise from time to time in the “ordinary course of business.” Most of the claims involve “complex issues” that are subject to uncertainties and the probability of a loss, the company added.

Dr. Reddy’s Headlines Two Dividend-paying Generic Pharmaceutical Stocks to Buy

However, Dr. Reddy’s rising share price since the end of 2020 shows that the stock’s fortunes have not succumbed to those risks. Aside from manufacturing generic pharmaceuticals, Dr. Reddy partnered with the Russian Direct Investment Fund on clinical trials and distribution of Sputnik V COVID-19 vaccine in India. Upon regulatory approval in India, RDIF agreed to supply Dr. Reddy’s with 100 million doses of the vaccine that is based on a well-studied human adenoviral vector platform to provide proven safety and to complete clinical trials to show its efficacy against COVID-19, the company announced.

Carlson commented that the coronavirus pandemic created supply shortages of compounds used to manufacture generic pharmaceuticals. There are no U.S.-based locations that produce the compounds, which put American generic drug manufacturers at a disadvantage to those in India and China, he added.

A potential problem for the India-based companies is that as the pandemic wanes, the U.S. Food and Drug Administration (FDA) will launch more extensive examinations of the factories in India than has been the case the last 18 months or so, Carlson said.

Two Dividend-paying Generic Pharmaceutical Stocks to Buy Offer Diversified Revenues

Dr. Reddy’s Laboratories operates three core segments: Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Its management described the company’s strengths as Chemical Synthesis, Formulation Development and Manufacturing; Clinical and Regulatory expertise; and robust global supply chain and strategic networks.

Analysts at Barclays PLC upgraded its rating of Dr. Reddy’s Laboratories on Feb. 2 to “overweight” from “equal weight” due to the company’s planned launch of its Sputnik vaccine. The heightened rating also included an increased price target of $70.00, up from $56.00. The stock subsequently showed those projections were conservative when the share price closed at $73.51 on July 13.

Chart courtesy of www.StockCharts.com

U.S. Money Manager Picks One of Two Dividend-paying Pharmaceutical Stocks to Buy

“Pure generic drug investment opportunities have become scarce over the years because success in that business is either predicated on moving up the industry food chain into proprietary products or reaching scale via consolidation,” said Hilary Kramer, who leads the GameChangers and Value Authority advisory services. “Either way, the number of companies focused on off-patent drugs shrinks over time as leaders move on and laggards get bought out.”

Paul Dykewicz conducts a pre-COVID-19 interview with Hilary Kramer, whose premium advisory services include IPO Edge, 2-Day Trader, Turbo Trader and the exclusive Inner Circle.

Investors focused on income probably are better off buying into a big pharmaceutical manufacturer like Viatris Inc. (NASDAQ:VTRS), a Canonsburg, Pennsylvania-based specialty and generics drug company that was formed by a merger between Pfizer’s (NYSE: PFE) Upjohn legacy brands business and Mylan, a generic and biosimilar drug manufacturer, Kramer said. Viatris has a “commanding franchise” and pays a 3% dividend as a bonus, Kramer counseled.

Viatris has fallen back in price so far this year, boosting the company’s dividend yield to 3.2%. It also lost money in 2020, so it is not without risk.

Chart courtesy of www.StockCharts.com

Amneal Offers Alternative to Two Dividend-paying Generic Pharmaceutical Stocks to Buy

“One pure play I’d recommend right now: Amneal Pharmaceuticals Inc. (NYSE:AMRX), which shot into the market spotlight with generic epinephrine pens,” Kramer said. “But even though that initial surge is flattening out now, the stock is still interesting here below $5. You’re effectively paying under six times earnings for long-term EPS expansion of around 12% a year, which is classically an attractive price for that kind of growth profile.”

Amneal Pharmaceuticals, based in Bridgewater, New Jersey, focuses on the development, manufacture and distribution of generic and specialty drug products. The company announced earlier in 2021 that the Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its Bevacizumab, with a standard review goal date of second-quarter 2022, according to the BsUFA (Biosimilar User Fee Act).

Chart courtesy of www.StockCharts.com

On April 5, Amneal completed its previously announced purchase of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC. Kashiv Specialty Pharmaceuticals focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.

Funds and Two Dividend-paying Generic Pharmaceutical Stocks to Buy Offer Income

Biotechnology stocks and funds have been doing well recently, and that’s likely to continue, Carlson said. Companies keep announcing breakthroughs, and a number of biotech companies are going public, he added.

It is not easy to identify the top stocks in the sector to buy. A diversified exchange-traded fund (ETF) could help many investors. But even that is difficult, because of differences in the stocks held by leading ETFs. Investors seeking alternatives to the two dividend-paying pharmaceutical stocks to buy can purchase shares directly in the two top biotech ETFs.

IBB Rose More Than 25% in Both 2019 and 2020

iShares Biotechnology (IBB) aims to track the NASDAQ Biotechnology Index, so it holds only stocks on the NASDAQ and that are classified as either biotechnology or pharmaceutical companies. This tends to be the more volatile of the two funds. Over some periods, its returns can be substantially higher or lower than funds.

IBB returned 25.21% in 2019, 26.01% in 2020 and 6.18% so far in 2021. Its dividend yield is just 0.1%.

XBI Carries Less Risk Than Two Dividend-paying Generic Pharmaceutical Stocks to Buy

The other fund is SPDR S&P Biotech (XBI), which tries to track the S&P Biotechnology Select Industry Index. The sector index is derived from a U.S. total market composite, so it is not limited to S&P 500 stocks. But the fund uses a sampling strategy to track the index instead of holding all the stocks. XBI tends to favor stocks with increased liquidity, so it does not own many small companies or those with limited trading volume.

Though it is less risky than IBB, XBI is more volatile than the market indexes and the health care sector. The fund returned 32.56% in 2019, 48.33% in 2020, but is down 10.52% so far in 2021.

The difficulty of categorizing stocks and funds in the sector is shown by Morningstar’s classification of both funds. IBB is in the Specialty-Technology category, while XBI is part of Specialty-Health.

IBB tends to hold larger capitalization companies than XBI. Despite their differences, Morningstar gives the two funds A correlation of 94%.

New Delta Variant of COVID-19 Spread

The increasingly transmissible Delta variant of COVID-19 has spread to almost every state in America, raising concerns among health officials about a surge in cases. Genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic, according to the Centers for Disease Control and Prevention (CDC).

A variant has one or more mutations that differentiate it from other COVID-19 varieties in circulation. The Delta variant is expected to become the dominant coronavirus strain in the United States, the CDC director warned. With more than half the U.S. population not fully vaccinated, public health officials caution that a resurgence of COVID-19 cases may well occur this fall when many unvaccinated children return to school.

Progress in increasing the number of people vaccinated from COVID-19 lifts hope that new cases and deaths will keep falling. As of July 16, 185,424,899 people, or 55.9% of the U.S. population, have received at least one dose of a COVID-19 vaccine. Those fully vaccinated total 160,686,878 people, or 48.3%, of the U.S. population, according to the CDC.

The Food and Drug Administration recently approved a third COVID-19 vaccine, manufactured by Johnson & Johnson (NYSE:JNJ), which requires only one dose rather than two, as with the first two vaccine providers: Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

COVID-19 cases worldwide have reached 189,441,350 and caused 4,073,985 deaths, as of July 16, according to Johns Hopkins University. U.S. COVID-19 cases totaled 34,051,383 and have led to 608,809 deaths. America has the dubious distinction as the country with the most COVID-19 cases and deaths.

The two dividend-paying generic pharmaceutical stocks allow investors to profit amid the pandemic. Rising COVID-19 vaccine availability, improving economic data and a recent $1.9 trillion federal stimulus package should help to lift the prices of the two dividend-paying generic pharmaceutical stocks to buy.

With a dividend yield of 24.2%, the highest-yielding dividend stock in 2021 is a buy with positive yearly returns and a growing customer base for its international shipping operation.

Frontline Ltd. (NYSE:FRO) is an international shipping company transporting crude oil and oil products through the Arabian Gulf, West African, North Sea and Caribbean. Its primary source of income is from its use of tankers to move large volumes of product, but Frontline also earns revenue via the purchase, resale and chartering of sea vessels.

The company is still small relative to the giants of the oil and gas midstream industry, with 84 employees and $1 billion in sales. However, with its projected growth in earnings and customer base, Frontline is a risky, albeit potentially lucrative, buy.

The Highest-Yielding Dividend Stock: Frontline’s Sales Fell But Are Expected to Rebound

Although the stock has seen a negative change in sales and earnings per share (EPS) over the trailing one-year period — dropping 24.2% and 41.8%, respectively — some of the Wall Street analysts covering Frontline have revised their earnings projections upward in the last month. With projected sales growth of 44.1% in the next year, analysts and institutional investors are becoming increasingly bullish about the shipping company.

The more notable projection is EPS, which analysts forecast will climb 520% in the next year, growing to more than six times its current value. This far exceeds the industry average expectation of 10.1%, while much of the oil and gas midstream industry struggles to recover from the COVID-19 pandemic.

Data provided by StockRover, start your free trial here.

Five analysts currently report on Frontline. One of them has issued a “strong buy” while the other four have maintained their “hold” rationale. Although the growth prospects of the company are highly attractive, it has performed poorly in the recent past and operates in a currently unstable industry and faces a fair amount of volatility.

The Highest-Yielding Dividend Stock: Frontline is the Most Efficient of its Peers

The shipping company reported a high net margin of 27.7% and a gross margin of 35.2%. What leads Frontline to excel above the rest of the industry, however, is its five-year average ranges for return on equity and return on assets — in these areas it sits in a far more sustainable position than many other companies with equally attractive margins.

Data provided by StockRover.

Equally notable are the valuation metrics when compared to other companies in its sector. Frontline sits in first place again, just surpassing Hess Midstream (NYSE:HESM) with a less expensive price-to-earnings (P/E) ratio and projected forward P/E ratio.

Data provided by StockRover.

This ranking shows long-term value in Frontline stock, making it a possible long-hold for price-conscious investors rather than just a high-growth stock to buy and sell.

The Highest-Yielding Dividend Stock: Frontline has a Dividend Yield of 24.2%

Frontline currently has the highest dividend yield of all stocks with positive one-year returns. Other stocks have been excluded from this screen — conducted using the Dividend Screener on DividendInvestor.com — due to their negative yearly returns partially inflating the dividend yield beyond the metric’s actual utility. Since dividend yield is a function of dividends paid over share price, a quickly falling share price will cause the dividend yield to look enticing at first glance before considering a company’s weakening condition.

As a result, we’ve opted to exclude those dividend stocks that show artificially inflated yields due to a plummet in a company’s value. Among companies with positive yearly returns — making the dividend yield “genuine” — none of Frontline’s peers come close to its massive 24.2% yield.

Data provided by StockRover.

Even among companies outside its industry, the next highest yield is Icahn Enterprises (NASDAQ:IEP) with a not-too-shabby 13.9%.

Note: Astute readers will notice the payout ratios for Frontline’s peers are all above 100%. For more information on this phenomenon and how companies can remain stable with payout ratios over 100%, read our article Why Do REITs Have High Payout Ratios?

There is a caveat to Frontline’s seemingly “too good to be true” dividend distribution: the company does not pay its dividend regularly. Rather, in times of high profit and high liquidity, Frontline rewards investors with high dividend payouts similar to how many companies pay special dividends.

In 2020, the shipping company paid a total of $1.60 throughout the year over three different distributions. In 2019, however, it paid a sole dividend of $0.10 in December. In 2018, the company paid no dividend at all.

Shown below is the company’s history for dividend distributions relative to stock price over the last 14 years. A big drop occurred in dividend payouts after 2007 and 2008, then again after 2010, 2011 and 2016. No dividend payouts occurred 2012- 2014.

Chart built using StockRover.

This uncertainty about future dividend payments also is what leads some analysts to maintain their “hold” rating. Bullish investors may view the EPS growth and profit increase in the near future as signs of increasing dividends Those more cautious will recognize the volatility of the industry overall alongside the lack of certainty in Frontline’s impressive dividends and choose to invest their money elsewhere.

With its large payout and incoming growth projections, the highest-yielding dividend stock in 2021 may be a worthwhile investment for dividend-hungry investors with the stomach to handle the risk.

Four dividend-paying biopharmaceutical investments to buy use genetics to produce growth and income amid the pandemic.

The four biopharmaceutical investments to buy that use genetics include two biopharmaceutical industry giants that have been building their genomic capabilities in recent years, as well as two exchange-traded funds that offer some exposure to the sector and hold enough traditional pharmaceutical stocks to provide investors a modest dividend yield. I am among those who are hoping and praying that genetic research breakthroughs one day may provide long-sought treatments for muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other diseases.

“Biotechnology stocks have been doing well recently, and that’s likely to continue,” said Bob Carlson, leader of the Retirement Watch investment newsletter. “Companies continue to announce breakthroughs, and a number of biotech companies are going public.”

Pension fund and Retirement Watch leader Bob Carlson answers questions from columnist Paul Dykewicz.

Four Dividend-paying Biopharmaceutical Investments to Buy Use Promising Genomic Medicine

“The field of genomic medicine is one of the most promising new areas in medicine,” said Jim Woods, editor of Intelligence Report and Successful Investing.

However, the favorite genomic medicine stocks of Woods are focused on growth and do not pay dividends.

Columnist Paul Dykewicz meets with Jim Woods, who heads the Intelligence Report and Successful Investing newsletters.

Genomic medicine stocks are part of the biopharmaceuticals category that is backed by an average of 3.5 years of cash to fund research and development (R&D) initiatives, compared to just 1.5 years at the peak of the 2008-09 financial crisis, according to BoA Global Research.

Funding of biopharmaceutical stocks has jumped since 2015, with more than $550 billion in cash amassed to keep these companies advancing their R&D programs, BoA wrote in a research note. Global spending on medicines is projected to produce a 3-6% compound annual growth rate (CAGR) through 2025 to total about $1.6 trillion, excluding spending on COVID-19 vaccines, according to a recent report by the IQVIA Institute for Human Data Science (NYSE:IQV). The report, “The Global Spending and Usage of Medicines,” relied on invoice price levels to forecast cumulative spending of $157 billion on COVID-19 vaccines through 2025, with the first wave of vaccines focused on approval by 2022.

Source: Stock Rover. Click here to sign up for a free two-week trial.

Four Dividend-paying Biopharmaceutical Investments to Buy Include Acquirers of Genomics Companies

Two major pharmaceutical companies that have expanded into biopharmaceutical and genetic treatments heavily are New York-based Bristol-Myers Squibb Inc. (NYSE:BMY) and Eli Lilly (NYSE:LLY).

“The real distinction for me at this point isn’t really about whether a drug developer draws on biotech materials or more conventional chemistry in order to treat illness,” said Hilary Kramer, who heads the GameChangers and Value Authority advisory services.

Chart courtesy of www.StockCharts.com

The first standalone biotech companies that went public in the 1980s have grown to be able to go “toe-to-toe” with big pharmaceutical companies and, in some cases, are now integrated into industry behemoths, Kramer continued. For example, Bristol-Myers Squibb acquired Celgene, said Kramer, who hosts the “Millionaire Maker” radio program and won a 2021 Gracie Award from the Alliance for Women in Media Foundation (AWMF) for the commercially syndicated program.

Paul Dykewicz interviews Hilary Kramer, who leads IPO Edge, 2-Day Trader, Turbo Trader and Inner Circle.

Eli Lilly Is One of Four Dividend-paying Biopharmaceutical Investments to Buy to Support Genomics

Eli Lilly and Company (NYSE:LLY) received a buy rating and a $225 price objective from BoA, based on its probability-adjusted net present value (NPV) analysis. The company’s key businesses and their valuations, according to BoA, include Neuroscience ($33/share), Oncology ($70/share), Immunology & Inflammation ($33/share), Diabetes ($89/share), and other pharmaceutical products and early pipeline assets ($15/share), with approximately -$15/share in net cash.

Possible risks to BoA’s $225 price objective are better-than-expected launches of competing products, emerging clinical data for pipeline assets that do not confirm prior observations, any failure to effectively commercialize approved products and potential drug pricing system restructuring in the United States. The company also received a subpoena in May 2021 from the U.S. Department of Justice requesting the production of certain documents relating to its manufacturing site in Branchburg, New Jersey.

Eli Lilly previously hired external counsel to conduct an independent investigation of certain allegations relating to its Branchburg manufacturing site. Eli Lilly, through its counsel, announced it is investigating the allegations thoroughly and cooperating fully with the investigation.

The negative news appeared to hurt the company’s stock price, but not profoundly. Such events can provide investors who are interested in buying shares a chance to do so at a slight discount.

Chart courtesy of www.StockCharts.com

iShares Biotechnology Earns Berth Among Four Dividend-paying Biopharmaceutical Investments to Buy

Carlson recommends a diversified exchange-traded fund (ETF) for most investors. However, even that is difficult, because of differences in the stocks held by the leading ETFs. The best move might be to hold positions in the two leading biotech ETFs, he concluded.

iShares Biotechnology (IBB) is designed to track the NASDAQ Biotechnology Index. So, it holds only stocks listed on the NASDAQ that are classified as either biotechnology or pharmaceutical companies, Carlson said. IBB tends to be the more volatile of the two funds and, over some periods, its returns can be substantially higher or lower than alternatives, Carlson cautioned.

Chart courtesy of www.StockCharts.com

Despite the volatility, IBB rose 25.21% in 2019, 26.01% in 2020 and 7.79% so far in 2021. Its annualized return is 14.24% for three years and 14.71% during the past five years, Carlson said.

Chart courtesy of www.StockCharts.com

SPDR S&P Biotech Snags Spot Among Four Dividend-paying Biopharmaceutical Investments to Buy

The other ETF Carlson recommended is SPDR S&P Biotech (XBI). That fund aims to track the S&P Biotechnology Select Industry Index. That biotech index is derived from a U.S. total market composite, so it is not limited to S&P 500 stocks. Instead, XBI uses a sampling strategy to try to track the index instead of holding all the stocks in the index.

“XBI tends to favor stocks with greater liquidity, so it doesn’t own many smaller companies or those with limited trading volume,” Carlson said.

Though it is less volatile than IBB, XBI is more volatile than the market indexes and the health care sector overall. The fund produced returns of 32.56% in 2019 and 48.33% in 2020, but so far in 2021 it has slipped 1.46%. Plus, the fund’s annualized returns are 13.01% during the past three years and 21.94% in the last five years.

Chart courtesy of www.StockCharts.com

CRISPR Therapeutics Offers Alternative to Four Biopharmaceutical Investments to Buy for Genomics

CRISPR Therapeutics (NASDAQ:CRSP), a non-dividend-paying, Swiss-American biotechnology company based in Zug, Switzerland, received an upgrade to “outperform” by Evercore ISI on May 13, along with a price target of $125 that the company has blown past in less than two months. The stock also roared beyond its $134 price target set by Citi when it boosted a rating on the stock to “neutral” from “sell” on June 11.

CRISPR Therapeutics is a biopharmaceutical company focused on developing what its management calls “transformative, gene-based medicines” for serious diseases. The company formed a partnership with Capsida Biotherapeutics Inc, which is dedicated to developing breakthrough gene therapies using fully integrated adeno-associated virus (AAV) engineering. The two companies collaborate to research, develop, manufacture and commercialize in vivo gene editing therapies that are delivered with engineered AAV vectors to treat familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia.

Four Dividend-paying Biopharmaceutical Investments to Buy for Genomics Breakthroughs Gain Lift

Under the agreement, CRISPR Therapeutics will lead research and development of the Friedreich’s ataxia program and perform gene-editing activities for both programs, while Capsida will spearhead research and development of the ALS program and conduct capsid engineering for both endeavors. Capsida’s high-throughput AAV engineering platform generates capsids designed to target specific tissue types and to limit transduction of tissues and cell types that are not relevant to the target disease in hopes of improving efficacy and safety.

CRISPR Therapeutics and Capsida each have the option to co-develop and co-commercialize the program that the other company leads. The companies would share equally all research, development and commercialization costs and profits of the collaboration.

Chart courtesy of www.StockCharts.com

Woods Weighs in on the Four Dividend-paying Biopharmaceutical Stocks to Buy for Genomics Advances

Woods wrote in June that CRSIPR announced positive data from clinical trials for CTX001, a potential one-time therapy under development with Boston-based Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) for patients enduring transfusion-dependent beta thalassemia and severe sickle cell disease.

“Blood disease therapies and other debilitating diseases that can be treated and cured by genomic companies are the next phase of this profoundly promising medical technology,” Woods opined.

BioNano Genomics Inc. (NASDAQ:BNGO), of San Diego, California, announced on July 6 that it has attained “significant progress” in China with the adoption of its Saphyr System for optical genome mapping (OGM) by WeHealth Shanghai, a provider of genome analysis services for reproductive health. The adoption was discussed at the Structural Variation Symposium in Shanghai, organized with support from the Shanghai Society of Genetics.

Chart courtesy of www.StockCharts.com

Multiple presentations were delivered on reproductive health at the symposium, with speakers highlighting a sizable need and opportunity in China with approximately 16 million births annually. Dr. Xiangdong Kong, based at The First Affiliated Hospital of Zhengzhou University, reported using optical genome mapping for prenatal testing in families with a history of facioscapulohumeral muscular dystrophy (FSHD), a form of muscular dystrophy.

BioNano Genomics received a “buy” recommendation on June 16 from the New York-based BTIG investment firm, along with a $10 price target. That projection would mark a 49.3% increase from the company’s price of $6.70 price late in the trading day on July 9.

Intellia Therapeutics Misses Making List of Four Dividend-paying Biopharmaceutical Stocks to Buy

Intellia Therapeutics Inc. (NASDAQ:NTLA), a Cambridge, Massachusetts-based biopharmaceutical company, is another recommendation of Woods but he is not the only one to like the stock. Another is money manager Hilary Kramer, who heads the GameChangers and Value Authority advisory services.

“We can rewrite the liver and other organs to remove genetic faults and, in theory, program tired tissue to rejuvenate itself,” Kramer said. “The hard part took years, but it’s over.”

Now, NTLA needs to develop specific applications, Kramer said. The real risk and returns have played out in the favor of shareholders with vision and long-term conviction, she added.

Chart courtesy of www.StockCharts.com

List of Four Dividend-paying Biopharmaceutical Investments to Buy Omits Editas Medicine

“Editas Medicine Inc. (NASDAQ:EDIT) has more room to run,” Kramer counseled. “Even if it only recovers its 52-week high, people who come in now can do quite well for themselves. The key is to keep your eyes on the frontier as technologies that felt like a dream years ago move inexorably toward commercialization.”

Chart courtesy of www.StockCharts.com

Non-dividend-paying CRSP, NTLA and Cambridge, Massachusetts-based EDIT do not qualify among the four biopharmaceutical investments to buy to capture genetic advances. Another non-dividend-payer is Precision BioSciences Inc. (NASDAQ:DTIL), a Durham, North Carolina-based clinical stage biotechnology company that is developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform.

“That’s where the long-term gains happen,” Kramer said.

For that reason, Kramer identified Precision BioSciences as her favorite genetic drug stock for the long run.

“That end of the industry provides the kind of experience a lot of investors want from biotech,” Kramer said.

Chart courtesy of www.StockCharts.com

Four Dividend-Paying Biopharmaceutical Investments to Buy Feature Genomics Amid COVID-19 Spread

The Delta variant of COVID-19 that has hit almost every state in America is raising concerns among health officials about potential new spikes in case numbers. Genetic variants of SARS-CoV-2 have been emerging and circulating worldwide throughout the COVID-19 pandemic, according to the Centers for Disease Control and Prevention (CDC).

A variant has one or more mutations that differentiate it from other varieties currently in circulation. The Delta variant is expected to become the dominant coronavirus strain in the United States, the CDC director recently said. With only 47.8%, or 158,629,431 people, in the U.S. population fully vaccinated, public health officials warn a resurgence of Covid-19 cases may occur this fall when many unvaccinated children are scheduled to go back to school.

Progress in COVID-19 vaccinations raises hope that new cases and deaths will be slowed. As of July 9, 183,542,871 people, or 55.3% of the U.S. population, have received at least one dose. President Joe Biden is among the elected officials in the United States who are encouraging people in the country who are eligible for COVID-19 vaccinations to obtain them.

The Food and Drug Administration (FDA) recently approved a third COVID-19 vaccine, manufactured by Johnson & Johnson (NYSE:JNJ), and that one requires just one does rather than the two doses needed with the first two vaccine providers: Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

Genomics Offer Hope From Four Dividend-Paying Biopharmaceutical Investments to Buy

COVID-19 cases worldwide totaled 184,546,452 and 3,991,715 deaths, as of July 9, according to Johns Hopkins University. U.S. COVID-19 cases reached 33,746,452 and have led to 605,905 deaths. America has the dreaded distinction as the country with the most COVID-19 cases and deaths.

The four dividend-paying biopharmaceutical investments to buy offer ways to support genomic research initiatives while seeking growth and income. Increased COVID-19 vaccine availability, an improving economy and a recent $1.9 trillion federal stimulus package may lift the valuations of the four biopharmaceutical investments to buy to reach heightened valuations as genetic research progress and potential breakthroughs are achieved.

31 dividend stocks poised to beat the market are identified by their free cash flow, explosive earnings per share (EPS) growth and “the magic formula.”

To outperform the S&P 500 — or, as they say, to beat the market — is the goal of fund managers and investors across the United States. But among active fund managers, those generally considered to be the elites of the investing world, 78% failed to outperform the market over the trailing five-year period.

Enter Barry Moore, who used the work of Joel Greenblatt and William O’Neil to develop a so-called “magic formula.” The stocks identified by this formula have beaten the market seven of the eight years since its development (underperforming in 2018), and are likely to do so again.

We selected only those stocks identified by the formula that pay a regular dividend and found 31 dividend stocks poised to beat the market. Since 2013, the S&P 500 has returned 214%. Our review of Moore’s magic formula during that time showed a return of 558%.

Listed below are the returns for the trailing eight-year period, where the blue line represents our selection of stocks from Moore’s formula and the red line shows the S&P 500 benchmark.

Chart provided by StockRover, start your free trial here.

And here are the returns in the trailing one-year period, where the 31 dividend stocks poised to beat the market have risen 134.1% and the S&P 500 has climbed 41.8%.

Data provided by StockRover.

The original set of stocks identified by Moore averaged a 25.4% increase year-over-year, compared to the S&P 500’s 13.8%.

The formula works by combining high free cash flows alongside explosive EPS (earnings per share) growth to return a baseline of quality stocks. From there, the list is narrowed down using a unique return on capital (ROC) formula and a modified earnings yield equation, both developed by Greenblatt. Our version then chops this list down further to include only those stocks that pay a regular dividend.

Using this formula, we identified 31 dividend stocks poised to beat the market. They are ranked in ascending order of quality in the table below.

Ticker	Sector	Consecutive Annual Dividend Hikes	Market Cap	Latest Close Price	Projected 12 Month Dividend Yield	Trailing 12 Month Dividend Yield
VVV	Consumer Products	4	$5.41B	$29.86	1.67%	1.63%
BGFV	Services	1	$516.24M	$23.16	3.11%	6.61%
STC	Financials	0	$1.53B	$57.09	2.31%	2.21%
DKS	Services	6	$6.64B	$101.28	1.43%	1.33%
BKE	Services	1	$2.14B	$42.95	3.07%	7.59%
BCC	Materials	3	$1.94B	$49.43	0.81%	8.09%
GPI	Services	0	$3.08B	$169.65	0.78%	0.55%
TGT	Services	49	$127.15B	$257.01	1.40%	1.06%
SEM	Health Care	0	$5.23B	$38.77	1.29%	0.32%
WSM	Services	14	$11.60B	$154.39	1.53%	1.45%
MLM	Materials	5	$21.88B	$350.74	0.65%	0.65%
MCY	Financials	19	$3.35B	$60.45	4.19%	4.18%
FIX	Industrials	8	$2.69B	$74.12	0.62%	0.60%
COKE	Consumer Products	0	$2.92B	$409.28	0.24%	0.24%
VCTR	Financials	1	$499.26M	$30.75	1.56%	1.11%
UI	IT & Communications	2	$18.93B	$301.32	0.53%	0.53%
FBHS	Consumer Products	7	$13.36B	$96.36	1.08%	1.04%
PRIM	Industrials	0	$1.53B	$28.45	0.84%	0.84%
LOGI	IT & Communications	3	$20.26B	$120.30	0.47%	0.47%
BIG	Services	0	$2.10B	$60.49	1.98%	1.98%
RCKY	Consumer Products	3	$358.69M	$49.25	1.14%	1.14%
PHM	Services	2	$13.80B	$52.49	1.07%	1.03%
ENSG	Health Care	7	$4.66B	$84.81	0.25%	0.24%
TPX	Consumer Products	0	$7.76B	$39.42	0.71%	0.36%
LEN__B	Services	1	$3.07B	$81.66	1.22%	1.22%
LEN	Services	1	$27.50B	$100.11	1.00%	1.00%
DHI	Services	6	$32.31B	$89.64	0.89%	0.86%
CCS	Industrials	0	$2.06B	$60.96	0.98%	0.25%
SBSW	Materials	0	$12.67B	$16.32	4.78%	4.81%
RILY	Financials	0	$1.83B	$67.11	14.90%	10.77%
LOMA	IT & Communications	0	$0	$7.64	3.27%	3.33%

The two top dividend-paying clothing companies to invest in include a casual fashion brand and a premium footwear manufacturer.

The apparel industry was brutally damaged by the COVID-19 pandemic — U.S. Census Bureau data lists it as one of the most negatively affected industries, with both the closure of malls that housed retail clothing stores and a general resistance from consumers to migrate to online clothes-shopping.

That said, the industry is recovering. The average company in the apparel retail industry has seen its stock grow 8.4% YTD (year to date) and 46.7% in the trailing one-year period. While these numbers seem fine, clothing is considered a basic staple and generally has very few high-growth companies. However, there are some that stand out both as strong dividend-payers and excellent companies for aggressive growth and long-term profits.

2 Top Dividend-Paying Clothing Companies to Invest In, According to DividendInvestor.com

These stocks were found and analyzed through our very own Dividend Screener on the Dividend Investor website. The Dividend Screener is a simple web-based tool that allows investors to sift through thousands of potential equities by adding their own customized criteria to find stocks that fit their portfolio’s unique needs.

Also used in the analysis of the two top dividend-paying clothing companies to invest in was the platform designed by our partners at Stock Rover, offering a rigorous screening program to assess performance metrics for investors. To sign up for a free two-week trial, click here.

For the greatest ease of use and most comprehensive research, we recommend that savvy investors use both the Dividend Screener and Stock Rover in tandem.

Here are the two top dividend-paying clothing companies to invest in.

2 Top Dividend-Paying Clothing Companies to Invest In: Rocky Brands Inc (NASDAQ:RCKY)

Rocky Brands Inc (NASDAQ:RCKY) is a premium footwear and apparel company headquartered in Nelsonville, Ohio, operating in a variety of business segments. The business is split into three primary categories: Wholesale, Retail and Military. Beneath these categories are a variety of individual name brands such as Rocky, Durango, Georgia Boot, Creative Recreation, Lehigh and Michelin footwear.

Where its wholesale and retail brands distribute footwear and apparel through several distribution channels — including over 10,000 stores across the United States and Canada and an international presence through its e-commerce division — Rocky Brands also sells directly to the U.S. military.

Rocky Brands has weathered the Coronavirus storm well. Although the company lost nearly 60% market value at the peak of the pandemic, its stock price has recovered and more than doubled from its pre-crisis price. RCKY has exhibited one-year returns of 176.5%, compared to the industry average of a 64% increase and a 41.4% increase in the S&P 500. RCKY is plotted alongside these two benchmarks in the chart below.

Chart provided by Stock Rover.

Rocky Brands has a stable quarterly dividend payment of $0.14, which has remained level since early 2019. The company pays an annual dividend of $0.56, which corresponds to a forward-yield of 1.0%. Its dividend is increasing steadily and has a five-year average annual growth rate of 4.9%.

The most attractive aspects of the stock are not its dividend payments, however — Rocky Brands’ growth prospects make it look like a buy. Sales have grown 18.9% in the last year and analysts project them to rise an additional 9.8% in the coming year. Additionally in the trailing 12-month period, we have seen earnings per share (EPS) increase 63.1% and earnings before income, taxes, depreciation and amortization (EBITDA) grow 54.6%. Similarly, EPS is projected to grow 9.3% in the coming year and EBITDA to rise 2.6%, continuing the company’s upward sales growth across all metrics.

These positive growth projections make Rocky Brands the fastest-growing company in its industry group, ranking 1st of 40 companies. This position is illustrated by the chart below, where RCKY is in the 97th percentile for EPS in its industry, etc.

Chart created using Stock Rover. To activate your free trial, click here.

A discounted cash flow (DCF) analysis using Stock Rover values the company stock at $60.65, approximately 8% higher than its latest closing price of $55.92.

2 Top Dividend-Paying Clothing Companies to Invest In: Buckle Inc (NYSE:BKE)

Buckle Inc. (NYSE:BKE), of Kearney, Nebraska, is a retailer for casual apparel, footwear and accessories targeting young men and women. Its product mix is aimed at a mid-range price-point and generally caters to fashion-conscious consumers.

The company has an impressive one-year return of 251.1%. Similarly to the above stock, BKE has been charted below for the trailing 12-month period alongside the industry norm and S&P 500 for the same period.

Chart created using Stock Rover. To activate your free trial, click here.

Buckle Inc. has a frequently-varying quarterly dividend payment of $0.33, which will next pay on July 29, 2021. This corresponds to a forward-yield of 2.6% but is potentially higher due to the company’s propensity to pay special dividends once per year. Its dividend is increasing steadily, having grown 10% from its late 2020 distribution of $0.30 to its current $0.33 quarterly value.

The most recent special dividend was $2.00 per share paid in December 2020, and it is difficult to know what the end-of-year special dividend payout will be post-2021.

Buckle is an enticing value stock, with strong financial performance and healthy growth prospects across the board. It has a P/E ratio of 12.4 and P/FCF (price over free cash flow) of 7.3, in addition to a low price over book value of 5.6. All of these indicate the future income and asset value wrapped into BKE stock is highly favorable and make the equity a definite buy for value investors.

Also favorable are the efficiency metrics of BKE when compared to the rest of the retail industry. Its return on assets is high, sitting at an impressive 21.7% (compared to RCKY’s 5.4%).

Chart created using Stock Rover. To activate your free trial, click here.

A discounted cash flow (DCF) analysis using Stock Rover values the company’s stock at $49.88, approximately 1% lower than its latest closing price of $50.14. While the company is unlikely to experience rapid growth to the same degree as Rocky Brands, Buckle is a long-term hold with the potential to offer significant value to its shareholders.

Three dividend-paying biopharmaceutical investments to purchase during the pandemic provide investors with a chance to profit from two exchange-traded funds (ETFs) and a stock that probably is less well-known than the names of companies that combined to create it.

The three biopharmaceutical investments to purchase are part of an industry that generally is well-financed and aims to treat health problems through biological solutions. Biopharmaceuticals are backed by an average of 3.5 years of cash to fund research and development (R&D) initiatives, compared to just 1.5 years at the peak of the 2008-09 financial crisis, according to BoA Global Research.

Funding of biopharmaceutical stocks has soared since 2015, with more than $550 billion in cash amassed to keep these companies advancing their R&D programs, BoA wrote in a June 29 research note. Global spending on medicines is projected to produce a 3-6% compound annual growth rate (CAGR) through 2025 to reach about $1.6 trillion by 2025, excluding spending on COVID-19 vaccines, according to a recent report by the IQVIA Institute for Human Data Science (NYSE:IQV). The report, “The Global Spending and Usage of Medicines,” relied on invoice price levels to forecast total cumulative spending of $157 billion on COVID-19 vaccines through 2025, with the initial wave of vaccinations focused on approval by 2022.

Oncology Treatments Help Drive the Three Dividend-paying Biopharmaceutical Investments to Purchase

In subsequent years, booster shots are expected to be required biannually, based on the length of immunity and the emergence of viral variants. Two therapy areas — oncology and immunology — each are forecast to grow at a 9-12% CAGR through 2025, spurred by increases in new treatments and medicine use, according to the institute.

Oncology alone is expected to add 100 new treatments in the next five years to contribute to a rise in spending of more than $100 billion, totaling over $260 billion in 2025. Immunology growth is projected to slow from its 17.3% CAGR of the past five years as reduced cost treatments offset growth in volume and drug launches.

In addition, many new therapies are expected in neurology. Treatments are targeting novel migraine therapies, rare neurological diseases and Alzheimer’s and Parkinson’s.

“Biotechnology stocks have been doing well recently, and that’s likely to continue,” said Bob Carlson, who heads the Retirement Watch investment newsletter. “Companies continue to announce breakthroughs, and a number of biotech companies are going public.”

Pension fund and Retirement Watch leader Bob Carlson answers questions from Paul Dykewicz.

Pension Fund Leader Likes Biotech ETFs as Two of the Three Dividend-paying Biopharmaceutical Investments to Purchase

It is “tough” to identify the top individual stocks in the biopharmaceutical sector, but Carlson said he recommends a diversified exchange-traded fund (ETF) for most investors. However, even that is difficult, because of differences in the stocks held by the leading ETFs. The best move might be to hold positions in the two leading biotech ETFs, he concluded.

Despite the volatility, IBB rose 25.21% in 2019, 26.01% in 2020 and 7.79% so far in 2021. Its annualized return is 14.24% for three years and 14.71% during the past five years, Carlson said.

Chart courtesy of www.StockCharts.com

SPDR S&P Biotech Snags Spot Among Three Dividend-paying Biopharmaceutical Investments to Purchase

“XBI tends to favor stocks with greater liquidity, so it doesn’t own many smaller companies or those with limited trading volume,” Carlson said.

Chart courtesy of www.StockCharts.com

The Three Dividend-paying Biopharmaceutical Investments to Purchase Are a Challenge to Categorize

The difficulty of classifying stocks and funds in the biopharmaceutical sector is shown by Morningstar’s placement of these two funds in different categories, with IBB put in Specialty-Technology and XBI going in Specialty-Health.

IBB tends to hold larger capitalization companies than XBI. Despite their differences, Morningstar indicated the two funds have a high correlation of 94%, Carlson said.

Pharmaceutical stocks, in general, are attractive, since they trade at a historically low valuation to the S&P 500, Carlson said., They sell at a 40% discount to the S&P 500, even though many pharmaceutical companies have improving drug pipelines and attractive growth prospects, Carlson added.

Pharmaceutical stocks and funds have pulled back in recent months partly due to uncertainty about drug-pricing legislation in Washington, Carlson said. Some people are advocating that Medicare should be allowed to negotiate prices directly with the pharmaceutical companies to reduce drug prices.

Three Dividend-paying Biopharmaceutical Investments to Purchase Gain Attention from Money Manager Kramer

The first standalone biotech companies that went public in the 1980s have grown to be able to go “toe-to-toe” with big pharmaceutical companies and, in some cases, are now integrated into industry behemoths, Kramer continued. For example, Celgene has been acquired by New York-based Bristol-Myers Squibb Inc. (NYSE:BMY), said Kramer, who hosts the “Millionaire Maker” radio program and won a 2021 Gracie Award from the Alliance for Women in Media Foundation (AWMF) for the commercially syndicated program.

“A few even pay dividends,” Kramer said.

Paul Dykewicz conducts a pre-COVID-19 interview with Hilary Kramer, whose premium advisory services include IPO Edge, 2-Day Trader, Turbo Trader and Inner Circle.

One Dividend-paying Stock Among the Three Dividend-paying Biopharmaceutical Investments to Purchase is Viatris

Dividend-paying Viatris Inc. (NASDAQ:VTRS), a Canonsburg, Pennsylvania-based pharmaceutical company, is a buy recommendation of BoA. The stock also enticed one of the company’s directors Don W. Cornwell to buy 2,000 shares on May 21 for an average price of $15.71. Since then, it has fallen 6.1% as of the close of trading on July 2. Investors might interrupt that dip after a director purchased shares as a signal that the current valuation may offer the shares at a slight discount.

Viatris, formed in November 2020 by a merger between Mylan and Upjohn, is in the S&P 500 and its portfolio includes more than 1,400 approved molecules for both non-communicable and infectious diseases. In addition, the medicines of Viatris are used by patients in more than 165 countries and territories.

Viatris reported financial results on May 10 for first-quarter 2021, with revenue reaching $4.4 billion. However, its generally accepted accounting principle (GAAP) net loss hit $1 billion for the same quarter The company reported adjusted earnings before interest, taxes, depreciation and amortization (EBIDTA) of $1.6 billion for the quarter, while GAAP net cash from operating activities came in at $849 million for Q1 2021.

On June 25, the European Union’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorisation for the medicinal product Abiraterone Mylan. The product is meant to treat of metastatic prostate cancer.

Further good news came on June 23, when the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan’s favor on its summary judgment motion in the class action suit related to EpiPen Auto-Injector. Company management issued a statement that it is pleased with the court’s decision to dismiss all of the plaintiffs’ claims under the federal RICO statute that were directed against Mylan’s former CEO Heather Bresch. The court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers.

The only remaining claim in this class action pertains to a patent settlement between Pfizer and Teva and other alleged actions affecting the launch of Teva’s generic epinephrine auto-injector. The ruling was not a decision on the merits of that claim and did not resolve the matter in the plaintiffs’ favor but the court’s action vindicated the company’s continued perseverance in defending itself against a series of claims over the past few years about EpiPen that have proven to be baseless, Viatris management opined. The company will have an opportunity to further defend itself in a trial scheduled to start September 7, 2021.

BoA Names Five Stocks to Buy Aside from the Three Dividend-paying Biopharmaceutical Investments to Purchase

Dublin, Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) received a $223 price objective (PO) and a buy recommendation from BoA Global Research, based on a valuation of 10.5x enterprise value (EV)/earnings before interest, taxes, depreciation and amortization (EBITDA) projected in 2022. BoA’s valuation multiple shows confidence that JAZZ will navigate concerns about the expiration of certain patents and the company’s growth profile.

The EV/EBITDA multiple of 10.5x compares to the company’s peer group that trades at 9x, which BoA described as appropriate based on JAZZ’s growth outlook compared to its rivals. However, JAZZ has risks that include possible slower-than-expected sales growth from its Vyxeos or Sunosi launches and weaker-than-expected sales growth of Xyrem, including failure to gain approval of next-generation formulations of Xyrem that could cause the pharmaceutical to lose its exclusivity prior to 2023.

Potential catalysts to help JAZZ exceed BoA’s price target include greater-than-expected sales growth from launching its Vyxeos chemotherapy or its narcolepsy treatment Sunosi. A second boost would be less-than-expected generic erosion of Xyrem (e.g., due to setbacks setting up a generic risk evaluation and mitigation strategy (REMS)), while a new plus would be future business development transactions becoming a key part of JAZZ’s strategy.

Chart courtesy of www.StockCharts.com

FibroGen Offers Alternative to Three Dividend-paying Biopharmaceutical Investments to Purchase

San Francisco-based FibroGen Inc. (NASDAQ:FGEN) gained a $43 price objective from BoA, based on a risk-adjusted discounted cash flow (DCF) analysis. Risks that may prevent FibroGen from meeting that price target include underperformance of the launch of its chronic-kidney-disease-related anemia drug Roxadustat vs. BoA projections, low demand or reduced net pricing and competitor data proving to be superior in efficacy and safety.

Possible catalysts for FibroGen to exceed the BoA price target on the stock could take shape if Roxadustat launch beats forecasts, its labeling for cardiovascular risk and cancer tops expectations and its competitor data reveal weaker efficacy and safety profile. BoA also wrote FibroGen’s Pamrevlumab monoclonal antibody to treat idiopathic pulmonary fibrosis and pancreatic cancer achieves key clinical milestones in 2022-23.

BoA wrote on June 22 that Roxadustat clearly has demonstrated efficacy. A key regulatory consideration will be the treatment’s safety and whether it meets historical statistical benchmarks, BoA added.

Chart courtesy of www.StockCharts.com

Assess Arena Pharmaceuticals With Three Dividend-paying Biopharmaceutical Investments to Purchase

Arena Pharmaceuticals (NASDAQ:ARNA), of San Diego, California, earned a buy rating and a price objective of $87 from BoA, based on a risk-adjusted DCF analysis. In BoA’s DCF, it assumed sales forecasts through 2036 for Etrasimod, a once-daily, oral S1P1,4,5 modulator undergoing multiple phase 3 trials for moderate to severe ulcerative colitis. That BoA assessment included the expected loss of exclusivity (LOE) in 2034, assuming a five-year patent term extension.

Risks that may prevent Arena Pharmaceuticals from achieving BoA’s price target include enhanced competition in Etrasimod’s target market to treat ulcerative colitis, if Ozanimod Ph3 clinical data to treat relapsing Multiple Sclerosis (MS) and inflammatory bowel disease substantially raise the bar for Etrasimod. Other risks could include Etrasimod failing to replicate Ph2 UC data in ongoing Ph3 and proving unable to demonstrate efficacy in Ph3 for atopic dermatitis, also known as eczema.

A reason for exceeding the price target may be Etrasimod producing impressive Ph3 data in treating atopic dermatitis, with clinical efficacy and safety similar to Dupixent, a prescription medicine used to treat people aged 6 and older who have moderate-to-severe eczema that is not well controlled. If so, Etrasimod may offer biologic-like efficacy but without the safety baggage of the Ph3 JAK inhibitors, according to BoA.

Chart courtesy of www.StockCharts.com

Applied Molecular Transport May Complement Three Dividend-paying Biopharmaceutical Investments to Purchase

BoA gave Applied Molecular Transport Inc. (AMTI), of South San Francisco, California, a buy recommendation and a price objective of $68 per share, based on a risk-adjusted, sum-of-the-parts DCF analysis. The investment firm forecast AMTI would keep developing new drug candidates, while risk-adjusting for possibilities that the company may be unable to secure durable molecule-specific patents after expiration of intellectual properties.

Possible risks to meeting the price target will include the outcome of Phase 2 clinical trials of AMT-101, a potential surprise emergence of competing platform for oral delivery of the treatment and possible dilution of existing shares issued at a discount.

Catalysts that could help the stock outperform expectations may include non-dilutive financing through a partnership or licensing that is not reflected in BoA’s forecast. Another catalyst would be a possible acquisition of the company at a premium price.

Chart courtesy of www.StockCharts.com

BeyondSpring Merits a Look in Addition to Three Dividend-paying Biopharmaceutical Investments to Purchase

New York-based BeyondSpring Pharmaceuticals (NASDAQ:BYSI) netted a buy rating and a $25 price objective from BoA, based on a risk-adjusted DCF analysis. The outlook hinged on key assumptions, including meeting cash flow forecasts through the 2036 patent life of Plinabulin, a small molecule under development and in a worldwide Phase 3 clinical trials to treat non-small-cell lung cancer. BoA projects that Plinabulin will produce $670 million in 2030 estimated risk-adjusted sales.

Possible risks to the company achieving the BoA price target could include a failure of Plinabulin to show desired results in clinical trials, slower-than-expected commercial uptake of that treatment in chemotherapy-induced neutropenia (CIN) and potentially dilutive cash raising efforts to commercialize the drug.

To outperform the price target, BeyondSpring might attain better-than-expected clinical data and commercial uptake of Plinabulin. The company also could be acquired at a premium price, according to BoA.

It is possible AMT-101 could produce the best in biologic efficacy and safety in its Phase 2 trial, according to BoA. That outperformance currently is not reflected in BoA’s market share model assumptions.

Chart courtesy of www.StockCharts.com

Kramer Names Other Stocks Aside from Three Dividend-paying Biopharmaceutical Investments to Purchase

As for Kramer’s favorite biopharmaceutical stocks, she praised Tarrytown, New York-baed Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), as well as Boston-based Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). All three stocks will give investors an experience similar to owning pharmaceutical goliaths, Kramer counseled. Those biotech stocks have generated billions of dollars in wealth for their shareholders, but may triple or quadruple again in the lifetime of current investors to become full-fledged industry giants, she added.

Chart courtesy of www.StockCharts.com

“But if your idea of biotech investing revolves more around the thrill of early-stage companies plotting moon shots on complicated disease targets, you want to stay small, diversified and patient,” Kramer said. “I’ve been talking about CRISPR gene editing technologies for at least a decade. Now, some of the most advanced names in the field are finally working their way around to human beings. As long as you have the patience, you can never be too early in the baby biotech world. But you can be too late. Once the big clinical data release hits the market, you’ll never get the same chance to invest in an unproven quantity again.

“Take Intellia Therapeutics Inc. (NASDAQ:NTLA), for example. Unless something goes seriously wrong, we probably won’t get a lot of entry points below $100. Those days are gone. Instead, buy the names that are out of favor.”

Chart courtesy of www.StockCharts.com

Right now, Kramer said she loves Iovance Biotherapeutics Inc. (NASDAQ:IOVA), of San Carlos, California, and its new spin on fighting cancer. It could easily be a $100 stock again over time, she added.

Chart courtesy of www.StockCharts.com

“I haven’t given up on Bluebird Bio Inc. (NASDAQ:BLUE),” Kramer said. “Similar target; huge potential. Precision BioSciences Inc. (NASDAQ:DTIL), which has been a real sleeper but could one day both cure diseases and global hunger with a single genetic platform. Of course, it might take years if it happens at all, so stay diversified and resilient. But if you are in biotech, odds are good you want to aim high.”

Chart courtesy of www.StockCharts.com

Deadly Delta Variant of COVID-19 Overshadows Three Dividend-paying Biopharmaceutical Investments to Purchase

The increasingly transmissible Delta variant of COVID-19 has spread to almost every state in America, raising concerns among health officials about potential future spikes in new cases. Genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic, according to the Centers for Disease Control and Prevention (CDC).

A variant has one or more mutations that differentiate it from other variants in circulation. The Delta variant is expected to emerge as the dominant coronavirus strain in the United States, CDC’s director said. With more than half the U.S. population not fully vaccinated, public health officials warn that a resurgence of Covid-19 cases could occur in the fall when many unvaccinated children are expected to return to school.

Progress in the COVID-19 vaccination process lifts hope that new cases and deaths will keep dropping. So far, 179,940,202 people, or 54.2% of the U.S. population, have received at least one dose. Those fully vaccinated total 154,199,664 people, or 46.4%, of the U.S. population.

In addition, the Food and Drug Administration (FDA) recently approved a third COVID-19 vaccine, manufactured by Johnson & Johnson (NYSE:JNJ), which requires only one dose rather than two, as with the first two vaccine providers: Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

COVID-19 cases worldwide reached 182,761,673 and caused 3,957,861 deaths, as of July 2, according to Johns Hopkins University. U.S. COVID-19 cases totaled 33,679,997 and have led to 605,038 deaths. America has the dubious distinction as the nation with the most COVID-19 cases and deaths.

The three dividend-paying biopharmaceutical investments to purchase offer investors ways to profit amid the pandemic while aiding the development of new treatments. Increased COVID-19 vaccine availability, an improving economy and the recent $1.9 trillion federal stimulus package should help to lift the valuations of the three dividend-paying biopharmaceutical investments to purchase.

The 100 most popular dividend stocks build a backlog of equities that every investor, whether optimistic or pessimistic, should know.

In fact, bulls and bears agree — knowing what is “in style” is a critical piece of information for investment strategy. While some investors buy popular stocks to ride their upward momentum, contrarians may see this collection of the 100 most popular dividend stocks as a list of possible short targets.

Whether your intention is to buy or sell contracts for the equities below, we chose the 100 most popular dividend stocks based on a number of criteria. First, every company listed must pay a regular dividend — it is worth noting that the size of these dividends varies considerably, with dividend yields ranging from 0.1% to 9.7%.

But after this initial criteria, we used a weighted combination of the 3-month average volume, short interest ratios, returns over several periods within the last year, price vs. 52-week high and moving average convergence and divergence (MACD) signals to create a general measure of popularity. This screen was created by using the Dividend Screener from DividendInvestor.com in tandem with the powerful technical screener Stock Rover. We recommend investors use a similar combination of tools when screening for their own portfolio’s specific needs.

Here are the 100 most popular dividend stocks, listed in order of least to most popular.

Ticker	Sector	Consecutive Annual Dividend Hikes	Market Cap	Latest Close Price	Projected 12 Month Dividend Yield	Trailing 12 Month Dividend Yield
GS	Financials	9	$126.63B	$372.71	2.15%	1.34%
KDP	Consumer Products	0	$50.64B	$35.73	2.10%	1.78%
KMI	Energy	3	$39.56B	$17.47	6.18%	6.05%
BK	Financials	10	$43.63B	$49.83	2.73%	2.49%
NEE	Utilities	19	$149.03B	$76.12	2.02%	1.93%
NLOK	IT & Communications	2	$14.91B	$25.71	1.94%	1.94%
FINV	Financials	0	$1.44B	$7.70	1.95%	1.95%
VFC	Consumer Products	0	$31.53B	$80.39	2.44%	2.43%
MRK	Health Care	9	$203.22B	$76.53	3.40%	3.35%
SLM	Financials	0	$5.87B	$19.18	0.63%	0.63%
JPM	Financials	10	$456.88B	$150.93	2.39%	2.39%
NKE	Consumer Products	3	$208.98B	$163.68	0.67%	0.65%
UNH	Financials	11	$392.36B	$415.77	1.40%	1.25%
PGR	Financials	0	$54.65B	$93.40	0.43%	5.25%
CNHI	Industrials	0	$21.58B	$15.94	Currency Mismatch	Currency Mismatch
COF	Financials	0	$72.88B	$161.43	0.99%	0.62%
MS	Financials	7	$177.82B	$95.57	1.46%	1.46%
ORCL	IT & Communications	7	$253.21B	$90.69	1.41%	1.23%
RDS__B	Energy	0	$51.06B	$37.01	3.76%	3.60%
RDSA	Energy	0	$76.50B	$38.09	3.49%	3.50%
BAC	Financials	7	$325.29B	$37.96	2.21%	1.90%
BCS	Financials	0	$15.34B	$9.20	1.20%	0.59%
APO	Financials	1	$13.59B	$58.51	3.42%	3.59%
APA	Energy	0	$18,250	$18.25	0.55%	0.55%
LYG	Financials	0	$3.45B	$2.42	2.48%	1.33%
SPG	Financials	0	$41.10B	$125.10	4.24%	4.24%
EMR	Industrials	64	$58.43B	$97.44	2.07%	2.07%
MPC	Energy	9	$34.84B	$53.39	4.35%	4.35%
SAN	Financials	0	$16.87B	$3.62	3.31%	3.44%
SID	Materials	0	$15.15B	$8.77	1.37%	1.41%
TXN	IT & Communications	17	$169.79B	$183.91	2.22%	2.15%
VLO	Energy	10	$25.95B	$63.48	6.18%	6.18%
MDLZ	Consumer Products	7	$89.68B	$63.84	1.97%	1.97%
NTR	Consumer Products	2	$36.24B	$59.56	3.09%	3.06%
CCJ	Materials	0	$6.84B	$17.27	Currency Mismatch	Currency Mismatch
ICE	Financials	7	$67.74B	$120.37	1.10%	1.05%
SBUX	Services	10	$144.49B	$122.63	1.47%	1.44%
SLB	Energy	0	$39.13B	$27.98	1.79%	1.79%
NLY	Financials	0	$11.80B	$8.44	10.43%	10.43%
ABEV	Consumer Products	1	$50.43B	$3.21	0.31%	2.53%
ING	Financials	0	$24.49B	$12.29	2.03%	1.00%
PXD	Energy	3	$35.09B	$143.85	1.56%	1.54%
SYF	Financials	4	$26.70B	$45.91	1.92%	1.92%
UPS	Industrials	11	$154.23B	$213.23	1.91%	1.90%
SWCH	IT & Communications	3	$2.73B	$20.85	0.96%	0.96%
HAL	Energy	0	$18.28B	$20.55	0.88%	0.88%
PEP	Consumer Products	49	$214.49B	$155.19	2.77%	2.67%
MA	Industrials	9	$375.63B	$382.16	0.46%	0.45%
DVN	Energy	3	$17.59B	$25.99	3.31%	4.31%

RTX	Industrials	0	$130.03B	$85.82	2.38%	2.25%
KO	Consumer Products	58	$243.48B	$56.47	2.98%	2.94%
BBVA	Financials	0	$19.87B	$6.12	2.29%	1.17%
AXP	Financials	9	$137.28B	$170.90	1.01%	1.01%
MRVL	IT & Communications	0	$47.51B	$57.98	0.41%	0.10%
EOG	Energy	3	$43.01B	$73.70	2.24%	3.49%
MUR	Energy	0	$3.20B	$20.75	2.41%	2.41%
BAM	Financials	9	$76.20B	$51.43	1.01%	0.97%
SM	Energy	0	$2.24B	$19.04	0.11%	0.11%
BAX	Health Care	4	$40.48B	$80.51	1.39%	1.26%
INFO	Industrials	0	$46.06B	$115.55	0.67%	0.64%
JCI	Consumer Products	0	$50.28B	$70.16	1.51%	1.51%
PM	Consumer Products	12	$151.55B	$97.24	4.94%	4.94%
BPY	Financials	7	$4.86B	$18.66	0.00%	5.35%
SCHW	Financials	5	$121.52B	$67.25	1.07%	1.07%
AAPL	IT & Communications	8	$2,449.74B	$146.80	0.60%	0.57%
MGM	Services	0	$19.24B	$39.23	0.03%	0.03%
FIS	Industrials	0	$90.61B	$146.11	1.07%	1.01%
MFA	Financials	0	$2.02B	$4.57	8.75%	6.56%
CTSH	IT & Communications	1	$35.92B	$68.11	1.41%	1.35%
BBD	Financials	0	$21.70B	$4.58	0.87%	3.62%
BX	Financials	1	$75.35B	$110.13	2.74%	2.44%
TGT	Services	49	$127.15B	$257.01	1.40%	1.06%
TWO	Financials	0	$1.72B	$6.29	10.81%	10.33%
COST	Services	2	$184.58B	$417.54	0.76%	3.09%
SWBI	Consumer Products	0	$1.13B	$23.57	1.36%	0.98%
LEN	Services	1	$27.50B	$100.11	1.00%	1.00%
VALE	Materials	0	$69.81B	$21.94	3.92%	7.17%
DHI	Services	6	$32.31B	$89.64	0.89%	0.86%
KKR	Financials	2	$35.32B	$60.71	0.96%	0.91%
KSS	Services	0	$7.82B	$50.05	2.00%	1.00%
FANG	Energy	2	$14.24B	$78.67	2.03%	1.97%
MSFT	IT & Communications	15	$2,155.08B	$286.14	0.78%	0.77%
GPK	Materials	0	$4.92B	$17.31	1.73%	1.73%
DHR	Health Care	3	$206.29B	$288.96	0.29%	0.27%
VRT	IT & Communications	0	$9.66B	$27.44	0.04%	0.04%
NVDA	IT & Communications	0	$488.28B	$195.94	0.08%	0.08%
LOW	Services	59	$139.09B	$196.77	1.63%	1.32%
HD	Services	11	$347.32B	$326.66	2.02%	1.93%
INFY	IT & Communications	0	$90.35B	$21.33	1.41%	1.42%
KR	Services	14	$29.69B	$39.73	2.11%	1.81%
AEO	Services	0	$5.81B	$34.67	2.08%	1.31%
T	IT & Communications	16	$199.99B	$28.01	7.43%	7.43%
LB	Services	0	$21.14B	$76.35	0.79%	0.20%
TJX	Services	0	$81.16B	$67.27	1.55%	0.77%
MDT	Health Care	43	$170.82B	$127.11	1.86%	1.86%
V	Industrials	12	$413.04B	$244.14	0.52%	0.52%
OXY	Energy	0	$25.21B	$27.01	0.15%	0.15%
CMCSA	Services	12	$264.94B	$57.79	1.73%	1.66%
XOM	Energy	38	$241.78B	$57.11	6.09%	6.09%

Dividend increases and dividend decreases, new dividend announcements, dividend suspensions and other dividend changes occur daily. To make sure you don’t miss any important announcements, sign up for our E-mail Alerts. Let us do the hard work of gathering the data and sending the relevant information directly to your inbox.In addition to E-mail Alerts, you will have access to our powerful dividend research tools. Take a quick video tour of the tools suite.

Eight dividend-paying pharmaceutical investments to purchase in pursuit of profits and income feature established industry behemoths and two exchanged-traded funds (ETFs).

The eight dividend-paying pharmaceutical investments to purchase should only be helped by global spending on medicines projected to grow at a 3-6% compound annual growth rate (CAGR) through 2025 to total about $1.6 trillion by 2025, excluding spending on COVID-19 vaccines, according to a recent report by the IQVIA Institute for Human Data Science (NYSE:IQV). The report, “The Global Spending and Usage of Medicines,” used invoice price levels to forecast $157 billion in total cumulative spending on COVID-19 vaccines through 2025, largely aimed at the initial wave of vaccinations through 2022.

In subsequent years, booster shots are expected to be needed on a biannual basis as the durability of immunity and the sustained emergence of new viral variants warrant. Two therapy areas — oncology and immunology — are each forecast to grow at a 9-12% CAGR through 2025, boosted by significant increases in new treatments and medicine use, according to the institute.

Oncology Therapies Will Aid Growth of the Eight Dividend-paying Pharmaceutical Investments to Purchase

Oncology alone is projected to add 100 new treatments in the next five years, contributing to increased spending of more than $100 billion to a total of more than $260 billion in 2025. Immunology growth is projected to slow from its 17.3% CAGR during the past five years as lower-cost treatments offset growth from volume and drug launches.

In addition, many new therapies are expected in neurology. Treatments are slated for novel migraine therapies, rare neurological diseases and Alzheimer’s and Parkinson’s.

Source: Stock Rover. Click here to sign up for a free, two-week trial for Stock Rover charts and analytics.

Amgen Ranks Among Eight Dividend-paying Pharmaceutical Investments to Purchase

Amgen, Inc. (NASDAQ:AMGN), of Thousand Oaks, California, received a price objective of $285 per share from BoA Global Research, providing the promise of an 18.8% increase from the closing price of $239.91 on June 22. The investment firm calculated its valuation of AMGN by using a sum of the parts net present value (NPV) analysis.

Potential risks to BoA’s price objective are faster-than-expected revenue erosion from legacy brands, slower-than-expected growth of new drug launches and clinical trial failures. However, Amgen’s prospects as one of the eight dividend-paying pharmaceutical investments to buy are boosted by the U.S. Food and Drug Administration’s approval in late May for the company’s new pharmaceutical for lung cancer patients who have a specific gene mutation, known as KRAS, which causes the disease to worsen after treatment with chemotherapy or other medicines.

The drug, sotorasib, will be sold under the brand name Lumakras. The treatment shrank tumors with the KRAS mutation in around 36% of patients who participated in clinical trials.

Lumakras is positioned for a strong launch due to its proven clinical profile, increasing testing and past targeted oncology launches, according to BoA. Plus, Lumakras has the potential to gain approval as part of a combination therapy to treat colorectal cancer.

Chart courtesy of www.stockcharts.com

BoA Forecasts ‘Strong Lumakras Launch’ for Amgen: One of Eight Dividend-paying Pharmaceutical Investments to Purchase

After Amgen’s American Society of Clinical Oncology (ASCO) conference call, BoA concluded the company is well positioned to meet the investment firm’s projections. BoA affirmed its buy rating and $285 price objective.

Amgen presented data that bolstered the drug’s commercial viability. The drug demonstrated impressive overall response rates (ORR) of roughly 35%, regardless of the number of prior lines of therapy, mutation type or tumor mutation burden.

Most notably, advanced patients with prior PD-1 therapy — but no platinum-based chemo — saw an ORR of 69%, compared to the overall population achieving 37%. Patient reported outcomes (PROs) showed stable overall quality of life measures, including overall health and physical functioning from baseline, during Lumakras treatment.

Relevant PRO measures of lung cancer symptoms, including cough, dyspnea and chest pain, remained stable or improved. When asked about how bothered they were by side effects of Lumakras, the vast majority, 85%, of recipients of the drug continued to be report that they were either “not at all” or only “a little bit” bothered.

Bristol-Myers Squibb Secures Place in Eight Dividend-paying Pharmaceutical Investments to Purchase

New York-based Bristol-Myers Squibb Co. (NYSE:BMY) gained a buy recommendation from BoA and received a $78 price objective (PO), based on a 50/50 blended average of its risk-adjusted discounted cash flow (DCF) and price-to-earnings (P/E) multiple applied to 2021 estimated earnings per share (EPS). The outlook projects an 18.3% rise in the company’s stock, following its closing price of $65.94 per share on June 22.

The investment firm’s discounted cash flow (DCF) analysis indicated a 10x 2021 P/E multiple, given an impending “patent cliff” and risks associated with a later-stage pharmaceutical pipeline. Possible risks that could halt Bristol-Myers Squibb from reaching BoA’s price target include uninspiring readouts from late-stage trials, more rapid deceleration of Revlimid erosion than expected, negative results from the company’s later-stage pipeline assets in development, calls from critics for drug price limits and negative patent rulings.

Bristol-Myers Squibb presented full details from its phase 3 RELATIVITY-047 trial during the ongoing American Society of Clinical Oncology 2021 meeting. The data topped expectations, while arguably achieving a better safety profile with less treatment-related adverse events and discontinuations, according to BoA.

Chart courtesy of www.stockcharts.com

Pension Fund Chairman Recommends Bristol-Myers Squibb as One of Eight Dividend-paying Pharmaceutical Investments to Purchase

Pharmaceutical stocks are attractive, since they trade at an historically low valuation to the S&P 500, said Bob Carlson, leader of the Retirement Watch investment newsletter. They sell at a 40% discount to the index, even though many pharmaceutical companies have improving drug pipelines and attractive growth prospects, Carlson added.

“The main drag on the sector is some uncertainty over drug-pricing legislation in Washington,” Carlson said.

Some people want to let Medicare negotiate prices directly with the companies to reduce drug prices. Despite the risk, Carlson said he likes dividend-paying BMY well enough to recommend it.

Carlson, who chairs the Board of Trustees of Virginia’s Fairfax County Employees’ Retirement System with more than $4 billion in assets, said Bristol-Myers Squibb is navigating the recent loss of patents and took on hefty debt last year to buy Celgene. The debt hurt Bristol-Myers Squibb’s share price and caused it to sell at a substantial discount to its value.

Income investors will appreciate that Bristol-Myers Squibb pays a “high dividend yield” of around 3.11% that looks to be safe, even after the debt payments from the Celgene deal are taken into account, Carlson said.

Pension fund and Retirement Watch leader Bob Carlson answers questions from Paul Dykewicz.

One of the Eight Dividend-paying Pharmaceutical Investments to Purchase Seeks to Improve Balance Sheet

Bristol-Myers Squibb has been selling assets and reducing expenses to increase cash flow, Carlson said. The company made deleveraging and improving its balance sheet a priority.

Carlson, who likes to invest in equities that pay dividends, said Bristol-Myers Squibb has a history of managing mergers and acquisitions well, so it is likely to attain the cost savings and benefits it projects from the Celgene deal. Plus, Bristol-Myers Squibb has a “good portfolio of profitable drugs and a solid pipeline” of others, Carlson added.

The company has at least maintained its dividend for more than 36 years and increased it each of the last 14 years. A risk to buying Bristol- Myers Squibb would be the possibility it would not execute its merger plan well and remain burdened with debt from the deal, Carlson cautioned.

“The risk has a low probability of being realized given the company’s history of successfully executing mergers,” Carlson said.

Collaboration on Cancer Drug Announced by One of the Eight Dividend-paying Pharmaceutical Investments to Purchase

Bristol-Myers Squibb announced jointly with Tokyo-based Eisai Co., Ltd. on June 17 that they had entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines an anti-folate receptor alpha (FRα) antibody that it developed with its anticancer agent eribulin, using an “enzyme cleavable linker.”

“It is a potential best-in-class FRα ADC with a favorable pharmacology profile and demonstrated single agent activity in patients with advanced solid tumors,” the companies stated in a press release.

Fund Offers Alternative to Eight Dividend-paying Pharmaceutical Investments to Purchase

In addition, investors should consider an exchange-traded fund (ETF) that’s diversified in the pharmaceutical sector, Carlson counseled. iShares US Pharmaceuticals (IHE) is among the oldest in the group and has had solid returns over the years, he added.

Chart courtesy of www.stockcharts.com

Top holdings in the fund recently were Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), Merck & Co. Inc. (NYSE:MRK), Zoetis (NYSE:ZTS), and Bristol-Myers Squibb. The fund owns about 46 stocks and has 78% of the fund in the 10 largest positions.

Eli Lilly Earns Spot Among Eight Dividend-paying Pharmaceutical Investments to Purchase

Eli Lilly and Company (NYSE:LLY) received a buy rating and a $225 price objective from BoA based on its probability-adjusted net present value (NPV) analysis. The company’s key businesses and their valuations, according to BoA, include Neuroscience ($33/share), Oncology ($70/share), Immunology & Inflammation ($33/share), Diabetes ($89/share), and other pharmaceutical products and early pipeline assets ($15/share), as well as approximately -$15/share in net cash.

Possible risks to BoA’s $225 price objective are better-than-expected launches of competing products, emerging clinical data for pipeline assets that do not confirm prior observations, failure to effectively commercialize approved products and potential drug pricing system restructuring in the United States. The company also received a subpoena In May 2021 from the U.S. Department of Justice requesting the production of certain documents relating to its manufacturing site in Branchburg, New Jersey.

The negative news appeared to hurt the company’s stock price, but not substantially. Such events can provide investors who are interested in buying shares a chance to do so at a slight discount.

Chart courtesy of www.stockcharts.com

A Second ETF Offers Investors a Chance to Gain Pharmaceutical Exposure, Woods Says

“One of the best ways to get exposure to the entire pharmaceutical space is via the outstanding exchange-traded fund (ETF), VanEck Pharmaceutical ETF (PPH),” said Jim Woods, editor of Intelligence Report and Successful Investing.

Woods recommends PPH as a tactical holding in both of his newsletters and he said his subscribers are up nearly 17% in the position thus far.

Paul Dykewicz interviews Jim Woods about top stocks.

The diversification in PPH includes exposure to the biggest and arguably best pharmaceutical firms in the world today, including AstraZeneca PLC ADR (NASDAQ:AZN), Sanofi (NASDAQ:SNY), Pfizer (NYSE:PFE), Novo Nordisk (NYSE:NVO), Bristol-Myers Squibb and Johnson & Johnson, Woods said. For investors who want big pharmaceutical company exposure, and particularly vaccine-producer exposure, PPH is the “best way” to obtain it, he added.

Chart courtesy of www.stockcharts.com

Money Manager Kramer Picks Three of the Eight Dividend-paying Pharmaceutical Investments to Purchase

“There are really two drug industries and the ones you buy should depend on the role they’ll play in your portfolio,” said Hilary Kramer, who heads the GameChangers and Value Authority advisory services.

For investors who are looking for a fairly “stable income source,” consider large pharmaceutical companies that offer dividend yields of at least 3%, Kramer said. Those companies do not typically develop “world-shaking blockbuster drugs” because all the major names ensure they get their share of attractive programs coming up from the smaller-stage developers to replace expiring patents, she added.

“The sum of the parts can shift as individual drugs win or lose market share, but the long-term landscape doesn’t change much from month to month,” Kramer counseled. On that basis, she highlighted Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK) and Sanofi SA (NYSE:SNY). All have robust vaccine businesses alongside other pharmaceutical operations and currently pay more than 3% a year in dividends.

“Accumulate on the dips,” Kramer said.

Chart courtesy of www.stockcharts.com

When other big pharmaceutical companies grow their way to higher yields, accumulate them, too, Kramer continued.

Paul Dykewicz conducts a pre-COVID-19 interview with Hilary Kramer, whose premium advisory services include IPO Edge, 2-Day Trader, Turbo Trader and Inner Circle.

Investors who are hunting for blockbuster drugs would need to invest in smaller pharmaceutical companies, Kramer counseled. Large pharmaceutical manufacturers are so big that even adding a $1 billion drug to the portfolio isn’t going to move the overall needle much farther than normal, she added.

Non-Dividend Iovance Biotherapeutics Offers Alternative to Eight Dividend-paying Pharmaceutical Investments to Purchase

“To get the real benefit of discovery, you need to go small,” Kramer said. “My current favorite name on that end is Iovance Biotherapeutics Inc. (NASDAQ:IOVA).”

Chart courtesy of www.stockcharts.com

The stock was upgraded to “market outperform” from “market perform” on June 10 by JMP Securities. The investment firm’s analyst Reni Benjami set a price target of $32 per share, roughly a 55% upside from the closing price of $24 per share on June 22.

Analysts have an average price target of $41 per share on the stock, according to FactSet. However, the analysts who cover the stock have a wide range of opinions about the company’s prospective value, with a low of $18 and a high of $83.

The company currently produces zero revenue, but it could have a cancer-fighting therapy past the Food and Drug Administration in 2023, assuming it isn’t bought out first, Kramer said. The stock can rise to $50 under the right conditions, Kramer added, while predicting the “fair value” could be double that price in the long haul.

Eight Dividend-paying Pharmaceutical Investments to Purchase Dodge Worst of COVID-19 Crisis

Progress in the COVID-19 vaccination process lifts hope that new cases and deaths will keep falling. As of June 25, 178,491,147 people, or 54% of the U.S. population, have received at least one dose. The fully vaccinated total 151,615,554 people, or 46%, of the U.S. population, according to the U.S. Centers for Disease Control and Prevention (CDC).

COVID-19 cases worldwide have hit 180,330,593 and caused 3,907,193 deaths, as of June 25, according to Johns Hopkins University. Also as of June 25, U.S. COVID-19 cases totaled 33,602,411 and have led to 603,523 deaths. America has the dubious distinction as the nation with the most COVID-19 cases and deaths.

The eight dividend-paying pharmaceutical investments to purchase give investors choices to a key industry that should retain demand for its products. Increased COVID-19 vaccine availability, an improving economy and a recent $1.9 trillion federal stimulus package likely will help to support the valuations of the eight dividend-paying pharmaceutical investments to purchase.

Assess Arena Pharmaceuticals With Three Dividend-paying Biopharmaceutical Investments to Purchase

Congress Comes for your Retirement Money

Search Dividend Investor